PLoS Computational BiologySystems BiologyPeer-reviewed journal article
Computational response modeling reveals context dependent Akt activity in luminal breast cancer cells
Cemal ErdemiD, Adrian V. LeeiD, D. Lansing TayloriD, Timothy R. LezoniD
Abstract
Aberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contributes to the risk and advancement of many cancer types by activating cell survival cascades. Mechanistic computational modeling of such pathways provides insights into each components role in the cell response. In previous computational models, the two receptors were treated as indistinguishable, missing the opportunity to delineate their distinct roles in cancer progression. Here, a dual receptor (IGF1R & InsR) computational model elucidated new experimental hypotheses on how differential early responses emerge. Complementary to our previous findings, the model suggested that the regulation of insulin receptor substrate (IRS) is critical in inducing differential MAPK and Akt activation. As predicted, perturbing ribosomal protein S6 kinase (RPS6K) kinase activity led to an increased Akt activation with insulin stimulation compared to IGF1 stimulation. Being able to discern differential downstream signaling, we can explore improved anti-IGF1R cancer therapies by eliminating emergence of compensation mechanisms, without disrupting InsR signaling. ImplicationsThe study shows, both experimentally and through computational models, that IGF1 and insulin receptor signaling pathways respond differently to RPS6K inhibition.
- Citations
- 4
- FWCI
- 0.31
- Field percentile
- 47th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer
Michael W. Lero, Jennifer S. Morgan, … Leslie M. J. Shaw·Journal of Biological ChemistryPeer-reviewed·Aug 10, 2026
- The Mixed Blessing of AMPK Signaling in Cancer Treatments
Mehrshad Sadria, Deokhwa Seo, Anita T. Layton·BMC CancerPeer-reviewed·Jan 25, 2022
- Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.
L. Ireland, A. Santos, … A. Mielgo·bioRxiv·Jul 23, 2017
- Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R inhibitors
A. Nagle, K. M. Levine, … A. V. Lee·Clinical Cancer ResearchPeer-reviewed·Oct 15, 2018
- Cancer causes dysfunctional insulin signaling and glucose transport in a muscle-type specific manner
S. H. Raun, J. Roland Knudsen, … L. Sylow·bioRxiv·Nov 3, 2021
- An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death
Mehdi Bouhaddou, Anne Marie Barrette, … Marc R. Birtwistle·PLoS Computational BiologyPeer-reviewed·Mar 26, 2018